Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Sickle Cell Disease Treatment Market from 2024 to 2025?
In recent times, there’s been significant expansion in the market for sickle cell disease treatment. The value is anticipated to swell from $2.95 billion in 2024 to $3.54 billion in 2025, reflecting a compound annual growth rate (CAGR) of 19.7%. Factors such as enhanced understanding of the disease, utilization of blood transfusions, pain management strategies, and hydroxyurea therapy, have driven this growth in the historical phase.
What Is the Projected Market Size of the Sickle Cell Disease Treatment Market?
The market size for sickle cell disease treatment is anticipated to witness a significant surge in the coming years. Its projected growth is expected to reach a valuation of $6.8 billion by 2029, with a compound annual growth rate (CAGR) of 17.7%. Factors contributing to this growth during the forecast period include advancements in gene editing and therapy, the development of new drugs, the implementation of telemedicine and remote monitoring, as well as various global health initiatives. Some of the major trends anticipated in the forecast period include therapeutic cures, alternative methods of pain management, worldwide collaborations, and initiatives to increase patient advocacy and engagement.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13048&type=smp
Who are the Major Competitors in the Sickle Cell Disease Treatment Market Outlook?
Major companies operating in the sickle cell disease treatment market are Sun Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Silver Lake Research Corporation0.45, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Medunik USA Inc., Zydus Cadila Healthcare Ltd., Graphite Bio Inc., Addmedica, Emmaus Medical Inc., Bluebird bio Inc., CRISPR Therapeutics AG, GlycoMimetics Inc., Arena Pharmaceuticals Inc., Mast Therapeutics Inc.
What Is Fueling Growth in the Sickle Cell Disease Treatment Market?
Anticipated growth of the sickle cell disease treatment market is closely tied to the escalating demand for blood transfusions. These transfusions, which involve transferring blood or blood products from a donor to a recipient, serve as an essential therapeutic strategy for those with sickle cell disease (SCD) because they enhance the ability of blood to transport oxygen and mitigate the issues related to vaso-occlusion. A case in point is a January 2022 report from Mid-Atlantic Long-Term Care, a provider of specialized round-the-clock triage on-call services in the US. The report pointed out that, on a daily basis in the US, there is a need for approximately 29,000 units of red blood cells, 5,000 units of platelets, and 6.500 units of plasma. Hence, this heightened demand for blood transfusions underscores their relevance in the expansion of the sickle cell disease treatment market. Predicted expansion of the sickle cell disease treatment market is also likely to be driven by an upswing in blood and bone marrow transplants. This medical procedure swaps out unhealthy blood-producing cells with healthy ones, aiming to cure sickle cell diseases and cancers by introducing healthy bone marrow cells into a person after their diseased bone marrow has been treated to eliminate the abnormal cells. These replacement cells may either come from the patient’s body (autologous transplant) or from a donor’s body (allogeneic transplant). A case in point is an instance in June 2024, when the National Transplant Organization (ONT), a Spain-based coordinating agency, reported that in 2023, Spain added 23,686 donors to its registry, marking an 8% increase from the previous year, and executed a maximum of 3,717 hematopoietic stem cell transplants, resulting in 77.4 transplants per million population. Consequently, the increasing number of blood and bone marrow transplants is likely to pep up the sickle cell disease treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=13048&type=smp
Which Sickle Cell Disease Treatment Market Segments Are Growing the Fastest?
The sickle cell disease treatment market covered in this report is segmented –
1) By Treatment Modality: Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant
2) By Disease Type: Sickle Cell Anemia, Hemoglobin Sickle C Disease (HbSC), Other Disease Types
3) By Route Of Administration: Oral, Parenteral
4) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Blood Transfusion: Regular Blood Transfusion, Exchange Transfusion
2) By Pharmacotherapy: Hydroxyurea, L-Glutamine, Voxelotor, Crizanlizumab
3) By Bone Marrow Transplant: Allogeneic Transplant, Autologous Transplant
Which Industry Trends Are Shaping the Future of the Sickle Cell Disease Treatment Market?
Prominent businesses in the sickle cell disease treatment market are prioritizing the development of new oral suspension drugs to augment patient adherence, improve drug efficacy, and facilitate more accessible treatment methods, specifically for pediatric and elderly patients. Oral suspension drugs are liquid medications that contain solid particles, aimed to aid easier ingestion especially for children or individuals who have difficulty taking pills. For example, Akums Drugs and Pharmaceuticals Ltd., an Indian pharmaceutical preparation manufacturer, introduced an ambient temperature-stable oral suspension of Hydroxyurea in March 2024. This affordable sickle cell disease medication, stable at room temperature, is designed to increase availability in India. At a cost below 1% of imported alternatives, it provides accurate dosage using oral syringes, proving advantageous for patients of all age groups without the need for cold storage.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/sickle-cell-disease-treatment-global-market-report
Which Countries Are Leading the Sickle Cell Disease Treatment Market?
North America was the largest region in the sickle cell disease treatment market in 2024. The regions covered in sickle cell disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13048
This Report Delivers Insight On:
1. How big is the sickle cell disease treatment market, and how is it changing globally?
2. Who are the major companies in the sickle cell disease treatment market, and how are they performing?
3. What are the key opportunities and risks in the sickle cell disease treatment market right now?
4. Which products or customer segments are growing the most in the sickle cell disease treatment market?
5. What factors are helping or slowing down the growth of the sickle cell disease treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model